'New era of growth': AstraZeneca sets out bold plans for $80bn revenues by 2030
The biggest company on London’s stock market, AstraZeneca, set out bold plans today for what it’s boss called “a new era of growth,” powered by 20 new drugs.
The Cambridge-based pharma giant has set a target of $80 billion revenue by 2030, and operating profits around $30 billion.
The rise, from hit the target it set ten years ago, as its board aimed to fend off a bid from Pfizer.
